Clinical Trial Update: Study of Immune Tolerance and Capacity for Wound Healing of Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB)

View source ↗

Summary

A completed clinical trial sponsored by INSERM studied immune tolerance and wound healing in patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Recessive Dystrophic Epidermolysis Bullosa

Snippet

Sponsor: Institut National de la Santé Et de la Recherche Médicale, France | Conditions: Recessive Dystrophic Epidermolysis Bullosa | Status: COMPLETED